PUBLISHER: Grand View Research | PRODUCT CODE: 1587476
PUBLISHER: Grand View Research | PRODUCT CODE: 1587476
The global vascular access devices market size is expected to reach USD 11.49 billion in 2030 and is anticipated to grow at a CAGR of 4.7% during the forecast from 2025 to 2030. The rise in the geriatric population, the prevalence of chronic illnesses, and the number of surgical operations all contribute to the market's expansion. The vascular system could be accessed with vascular access devices such that fluids, drugs, and blood can be administered or removed. For the treatment of severe medical illnesses including cancer and renal failure, these devices are frequently employed. The need for vascular access devices is anticipated to be driven by the rising prevalence of chronic disorders. Additionally, technological advancements in medical devices are also likely to support the growth of the market.
An increase in chronic illnesses including cancer, renal disease, heart disease, hypertension, diabetes, obesity, and depression has led to an increase in new cases of cancer. For instance, the GLOBOCAN 2020 report states that 19,292,789 new cancer cases were reported in 2020, out of which 2,261,419 and 2,206,771 were specifically related to breast cancer and lung cancer, respectively. Additionally, according to WHO data released in April 2021, chronic illnesses would cause the deaths of 41 million people per year (71% of all fatalities), with 77% of those deaths occurring in low- and middle-income countries. The demand for vascular access devices would be rising as cancer rates grow in the coming years.
Key players in the market are investing in the launch of new products and collaborations for sustaining their market presence. For instance, in September 2022, Access Vascular, Inc., partnered with the Association for Vascular Access (AVA). This partnership aims to enhance patient outcomes with evidence-based practices and tech education. Moreover, in May 2020, Smiths Medical (ICU Medical, Inc.) acquired Access Scientific, LLC's business; this transaction extends Smiths Medical's vascular access product portfolio.